epidermal growth factor

Recombinant proteinexperimental

Epidermal growth factor (EGF) is a protein that stimulates cell growth and differentiation by binding to its receptor, EGFR. Human EGF is 6-kDa and has 53 amino acid residues and three intramolecular disulfide bonds. — Wikipedia

Clinical trial activity

24 trials · 24 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
7
Phase 3
7
Phase 4
1

Earliest trial started May 1, 2007 (NCT00460265)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • egf
  • egf
  • epidermal growth factor
  • epidermal growth factor

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05724589N/AJan 30, 2023Institute of Dermatology, Thailand
NCT06044974Phase 4Jan 21, 2023Alexandria University
NCT04995354Phase 2/Phase 3 (Phase 3)Jun 1, 2022Cairo University
NCT04886726Phase 1Dec 1, 2021Henry Ford Health System
NCT04235296Phase 1Jan 17, 2020People's Liberation Army of China
NCT04375618Phase 1Oct 1, 2019SVS Institute of Dental Sciences
NCT05335720N/AJul 19, 2019Daewoong Pharmaceutical Co. LTD., Equilab International
NCT05219461Phase 1Mar 29, 2019Daewoong Pharmaceutical Co. LTD.
NCT04211597N/ASep 5, 2017Chang Gung University
NCT04704245N/AJul 20, 2017Catholic University of Korea, Hallym University
NCT02554851Phase 3Jan 1, 2017Oswaldo Cruz Foundation
NCT03047863N/ANov 1, 2016Catholic University of Korea
NCT03051880N/ANov 1, 2016Catholic University of Korea
NCT02748707Phase 2Aug 1, 2015Tata Memorial Hospital
NCT02284139Phase 2/Phase 3 (Phase 3)Apr 1, 2015Dong-A University
NCT01593995Phase 2May 1, 2012Dong-A University
NCT01566578Phase 1Apr 1, 2012Ennar Pharmaceuticals AF, University of Zurich
NCT01553708Phase 2/Phase 3 (Phase 3)Dec 1, 2011Chulalongkorn University, National Science and Technology Development Agency, Thailand
NCT01180062Phase 1Jan 1, 2011Pfizer, University of Kentucky, University of Toronto
NCT01308541Phase 1Jan 1, 2011Eisai
Showing 20 of 24 trials
Page 1 / 2

Organizations

Research & Development (24)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Daewoong Pharmaceutical Co. LTD.For profit5442009
Catholic University of KoreaAcademic/Hospital3212016
Dong-A UniversityAcademic/Hospital2222012
Alexandria UniversityAcademic/Hospital1112023
AmgenFor profit1112007
Cairo UniversityAcademic/Hospital1112022
Chang Gung UniversityAcademic/Hospital1112017
Chulalongkorn UniversityAcademic/Hospital1112011
EisaiFor profit1112011
Ennar Pharmaceuticals AFFor profit1112012
Equilab InternationalFor profit1012019
Hallym UniversityAcademic/Hospital1112017
Henry Ford Health SystemAcademic/Hospital1112021
Institute of Dermatology, ThailandAcademic/Hospital1112023
National Science and Technology Development Agency, ThailandGovernment1012011
Oswaldo Cruz FoundationAcademic/Hospital1112017
People's Liberation Army of ChinaGovernment1112020
PfizerFor profit1012011
Seoul National UniversityAcademic/Hospital1112009
SVS Institute of Dental SciencesAcademic/Hospital1112019
24 organizations
Page 1 / 2